[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Pharmacist-guided, Patient-driven Management of High Blood Pressure in CKD: A Novel Approach


Description

The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study. The study will further evaluate factors that may influence the Veteran to accept the self-management approach and what factors in the VHA healthcare system affect the implementation of the self-management approach.Chronic kidney disease (CKD) associates with high morbidity and mortality due to CKD progression and cardiovascular disease (CVD). Blood pressure (BP) lowering reduces the risk of CVD and CKD progression. In spite of the large number of BP medications available, a significant proportion of Veterans with CKD have BP above the goal. The current practice involves licensed providers performing medication titrations to achieve BP goals and is associated with lim

Trial Eligibility

Inclusion Criteria: * Age \>= 18 years, * CKD stage 3 or 4 (estimated GFR: 15-59 mL/min/1.73m2) or * Stage 2 CKD (estimated GFR 60-89 mL/min/1.73m2) with urinary albumin/creatinine ratio (ACR 300 mg/g if no DM and 30 mg/g if with DM), and * Uncontrolled hypertension defined as the avg of 2 readings \> 140 systolic. Exclusion Criteria: * Severely uncontrolled hypertension defined as systolic BP \>180, * Patients with resistant hypertension and taking 4 BP medications, * Orthostatic hypotension defined as reduced systolic BP by 20 mmHg or diastolic BP by 10 mmHg after 3 minutes of standing, * Severe CKD defined as estimated GFR \< 20 mL/min/1.73m2, * Life expectancy \<1 year, * Severe liver disease, * Severe congestive heart failure, * Severe cognitive decline due to dementia, * Pregnant, breastfeeding, or unwilling to use adequate birth control

Study Info

Organization

VA Office of Research and Development


Primary Outcome

Change in standardized office BP


Outcome Timeframe 12 months

NCTID NCT05546099

Phases PHASE3

Primary Purpose TREATMENT

Start Date 2022-12-15

Completion Date 2026-09-30

Enrollment Target 160

Interventions

BEHAVIORAL Self-management of BP medications

BEHAVIORAL Self-monitoring of home BP

Locations Recruiting

Iowa City VA Health Care System, Iowa City, IA

United States, Iowa, Iowa City


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Myelodysplastic Syndromes delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Myelodysplastic Syndromes Sponsors:

AbbVie
Bristol Myers Squibb

Follow Us

facebook instagram youtube